Cure8 research brief
Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person changes that carry risk.
Clinicians caring for adults with Crohn's disease, researchers studying prognostic biomarkers or monitoring strategies, and patients interested in more personalized monitoring approaches.
The researchers retrospectively analyzed 993 Crohn's patients (2005–2023) and linked longitudinal lab values to hospitalizations. They converted biomarkers into individualized z-scores and grouped them into drift categories to study time to first and recurrent hospitalizations.
Their analysis found that many routinely measured markers showed risk signals when measured relative to each patient’s baseline, including albumin, lymphocyte and monocyte percentages, potassium, and AST. The paper suggests personalized drift may catch risk that conventional thresholds miss, which could support earlier risk stratification if validated.
This is a preprint and describes retrospective associations rather than tested interventions; it does not establish that acting on these drift signals improves outcomes.
This is a retrospective, single-center preprint (medRxiv) using historical data; findings are associative and need external validation and prospective testing before routine clinical use. The paper analyzes many biomarkers, so results may need replication to rule out false positives.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
